The clinic study of patients with liver cavernous hemangioma treated with Pingyangmycin lipiodol emulsion

Objective:To evaluate safety and efficacy of superselectively hepatic artery embolization treatment with Pingyangmycin lipiodol emulsion for patients with liver cavernous hemangioma. Methods:23 patients with hepatic cavernous hemangioma underwent superselectively hepatic artery embolization with Pingyangmycin lipiodol emulsion. The changes of clinic symptoms,tumour diameters,and complications were observed before treatment and at 6 months and,at 12 months after treatment.Results:CT scans showed that the supplication of blood disappeared,and tumor diameter reduced in all patients at 6 months and 12 months after treatment. The lipiodol deposited well in the tumoral lesions of most patients. The mean tumor diameter was 8.01±2.2 cm before intervention,5.4±1.3 cm at 6 months after treatment,and 3.4±1.2 cm at 12 months after treatment. The clinic symptoms alleviate or disappear in all patients. No severe complications such as gallbladder injury,bile stuct strick,and liver function failure developed during and after therapy. Conclusion:Superselectively hepatic artery embolization treatment with Pingyangmycin lipiodol emulsion is an effectve and safe method for patients with hepatic cavernous hemangioma.